Learning about Our Medications
There is a difference in medicines.
The development of commercially available, human-derived gonadotropins has made pregnancy possible for countless women like you—medicines you and your doctor can trust for consistency, purity, and reliability of results.
At Ferring Pharmaceuticals, our dedication, plus more than 40 years of research and scientific expertise, have provided hope for millions of women who are struggling to conceive.
Our scientists are dedicated to finding innovative solutions to help you conceive. We invite you to learn more about Ferring fertility medications to help you fulfill your dream.
MENOPUR® and BRAVELLE®
MENOPUR® and BRAVELLE® are highly effective medications that contain the human hormones that can help you become pregnant. Developed to supplement your body’s own hormones, they have proven to have helped countless women around the world conceive.
You are invited to learn more about MENOPUR® and BRAVELLE®, then ask your physician if using MENOPUR® and BRAVELLE® is right for you.
ENDOMETRIN®: Progesterone designed with you in mind.
Progesterone is a natural hormone often prescribed for women undergoing Assisted Reproductive Technology (ART) treatment. Progesterone is one of the hormones essential for helping you to become and to stay pregnant.
ENDOMETRIN® is a vaginal insert that contains the hormone progesterone. The dose of ENDOMETRIN® is one insert placed in the vagina 2 or 3 times a day, for up to a total of 10 weeks. ENDOMETRIN® was shown to support excellent pregnancy rates in the largest IVF trial ever conducted in the United States with 1211 patients.1
We invite you to learn more about ENDOMETRIN® and to ask your doctor if ENDOMETRIN® may be right for you.
Ferring Pharmaceuticals
Helping you achieve what your heart dreams.
MENOPUR® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program. BRAVELLE® administered SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. BRAVELLE® administered SC or IM, in conjunction with hCG, is indicated for ovulation induction in patients who have previously received pituitary suppression.
ENDOMETRIN® administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.
Important Safety Information
Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe BRAVELLE® and MENOPUR®. BRAVELLE® and MENOPUR®, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (overall incidence of 6.0% for BRAVELLE® and 3.8% for MENOPUR®), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. BRAVELLE® and MENOPUR® are contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to respectively, urofollitropins, purified, and menotropins or MENOPUR®. BRAVELLE® is contraindicated for the presence of any cause of infertility other than anovulation. MENOPUR® is contraindicated for sex hormone dependent tumors of the reproductive tract and accessory organs. BRAVELLE® and MENOPUR® are contraindicated in women who are pregnant. BRAVELLE® may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of BRAVELLE® and menotropins when administered during pregnancy.
Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN®. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to 2% included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than 2%. ENDOMETRIN® is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness). ENDOMETRIN® is contraindicated in women who have or have had previous allergic reactions to progesterone or any of the ingredients in ENDOMETRIN®; a known missed abortion or ectopic pregnancy; liver disease; known or suspected breast cancer; active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
Click here to see Patient Prescribing Information for ENDOMETRIN®.
Click here to see Full Prescribing Information for MENOPUR®, BRAVELLE®, and ENDOMETRIN®.
Sharps Disposal Information
|
